89bio Inc. priced an upsized IPO at $16 a share, the midpoint of its price range.
Affimed NV priced its public offering for net proceeds expected to be approximately $28.2 million.
Agios Pharmaceuticals Inc. closed its underwritten public offering for gross proceeds of approximately $294.1 million.
Avita Medical Ltd. raised AU$120 million (US$81 million) in an institutional placement.
Azurrx Biopharma Inc. entered a $15 million common stock purchase and registration rights agreement with Lincoln Park Capital Fund LLC.
Biocryst Pharmaceuticals Inc. priced an underwritten public offering for expected gross proceeds of $55 million.
Cytokinetics Inc. agreed to sell $120 million of its 4% convertible senior notes due 2026 in an underwritten public offering.
Epicentrx Inc. raised $35 million in a series D financing.
Halozyme Therapeutics Inc. plans to offer to qualified institutional buyers $400 million in convertible senior notes due 2024.
Oasmia Pharmaceutical AB is conducting a new issue of shares with preferential rights of approximately SEK399 million (US$41.1 million).
Tot Biopharm International Co. Ltd. went public on Hong Kong’s stock exchange under the stock code of 1875 raising HK$511.4 million (US$61.3 million).
X-37 LLC said it closed a $14.5 million series A financing.
Aquestive Therapeutics Inc. licensed its Riluzole oral film for the treatment of amyotrophic lateral sclerosis in the EU to Zambon SpA.
Bayer AG and Dewpoint Therapeutics Inc. have signed a research, license and option agreement worth up to $100 million. The partnership will leverage Dewpoint’s platform for biomolecular condensates and Bayer’s small-molecule compound library to develop new treatments for cardiovascular and gynecological diseases.
Daré Bioscience Inc. entered an agreement to acquire Microchips Biotech Inc. that gains access to the company’s drug delivery technology, which has been validated in a first-in-human study in osteoporosis patients.
Foamix Pharmaceuticals Ltd. and Menlo Therapeutics Inc. are planning to merge to create a company focused on the commercialization and development of therapeutics to serve patients in the dermatology space.
Galectin Therapeutics Inc. entered a collaboration with Siemens Healthineers Inc. in nonalcoholic steatohepatitis and liver fibrosis.
Gossamer Bio Inc. signed a clinical collaboration agreement with Merck & Co. Inc. to evaluate the combination of its GB-1275, a modulator of CD11b, and Merck’s anti-PD-1 therapy, Keytruda (pembrolizumab), in patients with selected advanced solid tumors.
Merck & Co. Inc. acquired Calporta Therapeutics Inc. for an up-front payment and milestone payments that could total $576 million.
Samsung Bioepis Co. Ltd. will get $100 million up front in a commercialization deal for two of its biosimilar candidates with Biogen Inc. It will also be eligible for up to $270 million in milestone and option payments, as well as a share of sales revenue.
Sarepta Therapeutics Inc. and Stridebio Inc. signed a collaboration and license agreement to develop in vivo AAV-based therapies for up to eight central nervous system and neuromuscular targets.
Viome Inc. said it has partnered with Glaxosmithkline plc to increase understanding of chronic diseases and a potential role for vaccines.
Alkermes plc received a $150 million milestone payment from Biogen Inc. triggered by the recent FDA approval of Vumerity (diroximel fumarate) for relapsing forms of multiple sclerosis.
Anaptysbio Inc.’s phase IIb study of etokimab to treat moderate to severe atopic dermatitis failed to hit the primary endpoint in each dosing arms.
The Australian government has released a 10-year roadmap for stem cell research in Australia. The Stem Cell Therapies Mission will provide AU$150 million (US$102 million) under the Medical Research Future Fund to support stem cell research to deliver new therapies.
The Institute for Clinical and Economic Review is seeking comments, by Dec. 6, on its draft evidence report on acute treatments for migraine.
Fujifilm Corp. said it will make a capital investment of about ¥13 billion (US$1.2 billion) in the gene therapy field to further expand the contract development and manufacturing business.
Nanthealth Inc. has received FDA clearance for a whole exome sequencing test to determine overall tumor mutational burden in cancer tissue.
Red blood cell maturation drug luspatercept cleared the FDA for treating anemia in adults with beta-thalassemia who require regular red blood cell transfusions. Branded Reblozyl, the drug was developed by Celgene Corp. and Acceleron Pharma Inc.